176 related articles for article (PubMed ID: 18209781)
1. Increase of urinary 5-hydroxyindoleacetic acid excretion but not serum chromogranin A following over-the-counter 5-hydroxytryptophan intake.
Joy T; Walsh G; Tokmakejian S; Van Uum SH
Can J Gastroenterol; 2008 Jan; 22(1):49-53. PubMed ID: 18209781
[TBL] [Abstract][Full Text] [Related]
2. 'Sweet Dreams', 'Happy Days' and elevated 24-h urine 5-hydroxyindoleacetic acid excretion.
Hallin ML; Mahmoud K; Viswanath A; Gama R
Ann Clin Biochem; 2013 Jan; 50(Pt 1):80-2. PubMed ID: 23086978
[TBL] [Abstract][Full Text] [Related]
3. Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors.
Pavel ME; Phan AT; Wolin EM; Mirakhur B; Liyanage N; Pitman Lowenthal S; Fisher GA; Vinik AI;
Oncologist; 2019 Apr; 24(4):463-474. PubMed ID: 30355775
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A as an alternative to 5-hydroxyindoleacetic acid in the evaluation of symptoms during treatment of patients with neuroendocrine Tumors.
Korse CM; Bonfrer JM; Aaronson NK; Hart AA; Taal BG
Neuroendocrinology; 2009; 89(3):296-301. PubMed ID: 18840995
[TBL] [Abstract][Full Text] [Related]
5. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
Takahashi S; Takahashi R; Masumura I; Miike A
Folia Psychiatr Neurol Jpn; 1976; 30(4):461-73. PubMed ID: 1087913
[TBL] [Abstract][Full Text] [Related]
6. The effect of oral 5-HTP administration on 5-HTP and 5-HT immunoreactivity in monoaminergic brain regions of rats.
Lynn-Bullock CP; Welshhans K; Pallas SL; Katz PS
J Chem Neuroanat; 2004 May; 27(2):129-38. PubMed ID: 15121217
[TBL] [Abstract][Full Text] [Related]
7. Measurement of 5-hydroxyindole compounds during L-5-HTP treatment in depressed patients.
Takahashi S; Takahashi R; Masumura I; Miike A
Folia Psychiatr Neurol Jpn; 1976; 30(4):463-73. PubMed ID: 1088138
[TBL] [Abstract][Full Text] [Related]
8. Daily cyclic changes in the urinary excretion of 5-hydroxyindoleacetic acid in patients with carcinoid tumors.
Zuetenhorst JM; Korse CM; Bonfrer JM; Peter E; Lamers CB; Taal BG
Clin Chem; 2004 Sep; 50(9):1634-9. PubMed ID: 15247155
[TBL] [Abstract][Full Text] [Related]
9. Limited value for urinary 5-HIAA excretion as prognostic marker in gastrointestinal neuroendocrine tumours.
Zandee WT; Kamp K; van Adrichem RC; Feelders RA; de Herder WW
Eur J Endocrinol; 2016 Nov; 175(5):361-6. PubMed ID: 27491374
[TBL] [Abstract][Full Text] [Related]
10. Urinary serotonin in the diagnosis of carcinoid tumors.
Feldman JM
Clin Chem; 1986 May; 32(5):840-4. PubMed ID: 2421946
[TBL] [Abstract][Full Text] [Related]
11. Urinary free cortisol excretion in patients with hyperserotoninaemia from the carcinoid syndrome.
Feldman JM
Clin Endocrinol (Oxf); 1979 Nov; 11(5):541-8. PubMed ID: 316372
[TBL] [Abstract][Full Text] [Related]
12. Serotonin metabolism in patients with carcinoid tumors: incidence of 5-hydroxytryptophan-secreting tumors.
Feldman JM
Gastroenterology; 1978 Dec; 75(6):1109-14. PubMed ID: 309417
[TBL] [Abstract][Full Text] [Related]
13. On the tryptophan-serotonin metabolism in manic-depressive disorders. Changes in plasma 5-HT and 5-HIAA levels and urinary 5-HIAA excretion following oral loading of L-5HTP in patients with depression.
Amamoto T; Sarai K
Hiroshima J Med Sci; 1976 Sep; 25(2-3):135-40. PubMed ID: 1088369
[No Abstract] [Full Text] [Related]
14. 5-hydroxytryptamine metabolism in sheep.
Bartlet AL
Br J Pharmacol; 1971 Jun; 42(2):273-80. PubMed ID: 5314578
[TBL] [Abstract][Full Text] [Related]
15. Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome.
Keszthelyi D; Troost FJ; Jonkers DM; van Eijk HM; Lindsey PJ; Dekker J; Buurman WA; Masclee AA
Aliment Pharmacol Ther; 2014 Aug; 40(4):392-402. PubMed ID: 24943480
[TBL] [Abstract][Full Text] [Related]
16. Plasma accumulation of metabolism of orally administered single dose L-5-hydroxytryptophan in man.
Magnussen I; Jensen TS; Rand JH; Van Woert MH
Acta Pharmacol Toxicol (Copenh); 1981 Sep; 49(3):184-9. PubMed ID: 6175178
[TBL] [Abstract][Full Text] [Related]
17. Improved diagnosis of carcinoid tumors by measurement of platelet serotonin.
Kema IP; de Vries EG; Schellings AM; Postmus PE; Muskiet FA
Clin Chem; 1992 Apr; 38(4):534-40. PubMed ID: 1373675
[TBL] [Abstract][Full Text] [Related]
18. Clinical effects of octreotide compared to placebo in patients with gastrointestinal neuroendocrine tumours. Report on a double-blind, randomized trial.
Jacobsen MB; Hanssen LE
J Intern Med; 1995 Mar; 237(3):269-75. PubMed ID: 7534331
[TBL] [Abstract][Full Text] [Related]
19. Plasma chromogranin A marks emesis and serotonin release associated with dacarbazine and nitrogen mustard but not with cyclophosphamide-based chemotherapies.
Cubeddu LX; O'Connor DT; Hoffmann I; Parmer RJ
Br J Cancer; 1995 Oct; 72(4):1033-8. PubMed ID: 7547218
[TBL] [Abstract][Full Text] [Related]
20. Serum levels of 5-hydroxyindole derivates after administration of L-5-hydroxytryptophan ethyl ester.
Korf J; Sebens JB; Venema K; van Praag HM
Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):171-82. PubMed ID: 968174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
